A model for predicting the time of early symptomatic restenosis after infrapopliteal angioplasty in patients with critical limb ischemia

被引:0
作者
Takashi Yanagiuchi
Taku Kato
Takanori Hiroe
Junki Yabuta
Katsuyuki Hanabusa
Yutaro Ota
Tsubasa Komai
Shinya Yamazaki
Shunpei Ushimaru
Ritsuko Kurimoto
Hirokazu Yokoi
Hiroki Mani
Kan Zen
Satoaki Matoba
机构
[1] Rakuwakai Otowa Hospital,Department of Cardiology
[2] Kyoto University Graduate School of Medicine,Department of Biostatistics/Medical Education Center
[3] Kyoto Prefectural University of Medicine,Department of Cardiovascular Medicine
来源
Cardiovascular Intervention and Therapeutics | 2021年 / 36卷
关键词
Endovascular treatment; Critical limb ischemia; Balloon angioplasty; Infrapopliteal lesion; Restenosis;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study is to develop a model for predicting the time of early symptomatic (delayed or nonhealing wound) restenosis after infrapopliteal angioplasty in patients with critical limb ischemia (CLI). This is a single-center retrospective cohort study evaluating 60 de novo infrapopliteal lesions of 38 limbs in 35 patients with CLI, who underwent successful endovascular treatment (EVT) from October 2016 to December 2018 and follow-up angiography within 3 months from the procedure. Outcome measures were binary restenosis at follow-up angiography and clinical outcome at 3 months. Patient/limb/lesion characteristics were compared between the restenosis and non-restenosis groups. Angiographic restenosis predictors were assessed to develop a model for predicting the time of restenosis using multinomial logistic regression. The restenosis rate at follow-up angiography (median time, 41 days [IQR 27–58 days]) was 38% (23/60). After adjustment for covariables, longer period between EVT and follow-up angiography and lower C-reactive protein (CRP) were the predictors of angiographic restenosis. We developed a model for predicting the time of early symptomatic restenosis with a probability of 70%: “Days = 200 − 2.1 age − 13 CTO + 3.3 CRP” (R2 = 0.81, RMSE = 0.27), e.g., 80 years old, CTO (+), CRP 4.4 mg/dl: 32.2 days. The predictive model including age, CTO, and CRP might allow estimation of the period for the angiographic restenosis development.
引用
收藏
页码:330 / 337
页数:7
相关论文
共 99 条
  • [1] Norgren L(2007)Inter-society consensus for the management of peripheral arterial disease (TASC II) Eur J Vasc Endovasc Surg 33 1-75
  • [2] Hiatt WR(2007)Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity Eur J Vasc Endovasc Surg 33 453-460
  • [3] Dormandy JA(2001)Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up Circulation 104 2057-2062
  • [4] Nehler MR(2005)BASIL trial participants. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicentre, randomized controlled trial Lancet 366 1925-1934
  • [5] Harris KA(2010)Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis Ann Surg 252 765-773
  • [6] Fowkes FG(2010)Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease Catheter Cardiovasc Interv 76 1047-1054
  • [7] Graziani L(2012)Angiographic restenosis and its clinical impact after infrapopliteal angioplasty Eur J Vasc Endovasc Surg 44 425-431
  • [8] Silvestro A(2012)Major adverse limb events and wound healing following infrapopliteal artery stent implantation in patients with critical limb ischemia: the XCELL trial Catheter Cardiovasc Interv 80 1042-1051
  • [9] Bertone V(2012)Predictors of adverse clinical outcomes after successful infrapopliteal intervention Catheter Cardiovasc Interv 80 861-871
  • [10] Manara E(2015)Predictors of delayed wound healing after endovascular therapy of isolated infrapopliteal lesions underlying critical limb ischemia in patients with high prevalence of diabetes mellitus and hemodialysis Eur J Vasc Endovasc Surg 49 565-573